Research articlePublished 22 Dec 2011
VEGF 165 Gene Therapy Improves Left Ventricular Function and Exercise Capacity in Diabetic Rats after Myocardial Infarction: Impact on Mortality Rate
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Despite the increased amount of evidence about the benefits of human vascular endothelial growth factors by plasmid (pHuVEGF165) based gene transfer after an ischemic event, the effects of pHuVEGF165 therapy in diabetic hearts after myocardial infarction (MI) remains poorly investigated. We evaluated the effects of intramyocardial pHuVEGF165 injection on left ventricular (LV) morphometry, function and blood flow, maximal oxygen consumption (VO2max), and the total mortality rate of diabetic rats after MI. Male Wistar rats were divided into control (C), myocardial infarction+saline injection (I+SAL), myocardial infarction+pHuVEGF165 injection (I+VEGF), diabetes+myocardial infarction+saline injection (DI+SAL), and diabetes+myocardial infarction+pHuVEGF165 injection (DI+VEGF). MI was induced after 15 days of streptozotocin diabetes induction. One day after MI, the animals received pHuVEGF165 or saline intramyocardial injection. LV function and maximal oxygen consumption (VO2max) were evaluated at the initial injection and 30 days after injections. MI area evaluation showed an additional reduction in DI+VEGF (8±1%) in comparison with group I+VEGF (31±3%). Improvement in systolic function, evaluated invasively and noninvasively, lung wet/dry weight ratio, and VO2max were observed in both pHuVEGF165 injected groups. Consequently, mortality rate was reduced in I+VEGF (19%) and DI+VEGF (12.5%) when compared with I+SAL (48%) and DI+SAL (37.5%) groups. In conclusion, pHuVEGF165 therapy resulted in reduced MI area, stabilization and maintenance of left ventricular function, increased VO2 max, and reduced mortality in MI animals, diabetic or not. These results highlight the importance of continuing experimental studies and controlled clinical trials of gene therapy for ischemic cardiomiopathy associated with the pathological conditions of diabetes.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectDiabetes & Endocrinology
- SubjectGenetics & Molecular Biology
- SubjectPhysical Therapy & Rehabilitation